Navigation Links
New Drug May Put the Squeeze on Heart Failure
Date:8/19/2011

By Denise Mann
HealthDay Reporter

THURSDAY, Aug. 18 (HealthDay News) -- An experimental heart failure drug may change the way doctors treat this vexing condition, researchers say.

Heart failure, also called congestive heart failure, occurs when the heart can no longer pump strongly enough for blood to the reach the rest of the body. About 5.7 million people in the United States have heart failure, and 300,000 people die from it each year, according to the U.S. National Heart, Lung, and Blood Institute. While no cure exists, treatments focus on improving quality of life and helping people live longer.

A new drug -- omecamtiv mecarbil, which is being developed by Cytokinetics Inc. in San Francisco -- may someday offer an alternative to current treatments, according to the results of two clinical trials published Aug. 20 in a special issue of The Lancet.

"It improves heart function in a completely new and unique manner," said Dr. John R. Teerlink, a cardiologist at the San Francisco Veterans Affairs Medical Center and author of one of the new studies.

"The drug directly increases the activation of certain heart muscle proteins, effectively recruiting 'more hands on the rope' with each heartbeat," he said. "By improving the efficiency and performance of the heart, it is our hope that patients with heart failure will actually feel better with fewer symptoms of fatigue and shortness of breath, and perhaps even live longer," he said.

However, it is too early to draw any sweeping conclusions, as the drug -- called a cardiac myosin activator -- is in the early stages of clinical trials.

The currently available heart failure drugs, such as milrinone (Primacor) and dobutamine (Dobutrex), indirectly increase heart function, and can cause dangerous, even deadly, heart rhythm abnormalities, Teerlink said. "These drugs are 'necessary evils' because they are the only currently available pharmacologic means to increase heart function," he said.

Teerlink's study involved 34 healthy men who received the drug intravenously once a week for one month. It was designed to determine the optimal dosing regimen for the new drug.

The other study, conducted at the University of Hull in East Yorkshire, England, marks the first time that the agent was studied in people with heart failure. The researchers said omecamtiv mecarbil safely improved cardiac function in 45 people with heart failure who were already receiving standard treatment.

Dr. Ronald Zolty, director of the heart failure program at the Albert Einstein College of Medicine in New York City, is cautiously optimistic about the new heart failure drug.

"It is a promising drug, but we have been down this road before," he said.

"When you have heart failure, the pumping action of the heart is weak, so not enough blood gets to the body, and you feel short of breath, sleep a lot and your kidneys don't work," Zolty explained.

Existing drugs do improve the "squeeze," but they also increase mortality, he said.

Dr. Michele Hamilton, director of the heart failure program at Cedars-Sinai Heart Institute in Los Angeles, agreed with Zolty on the need for a new heart failure drug.

"The major problem we face in treating heart failure is how can we make the heart squeeze harder," she said. To date, no medications have proven effective or safe, and as a result, doctors focus on getting rid of excess fluid buildup and reducing stress on the heart, she said.

Medications that make the heart squeeze harder put more stress on the heart, and the patients die sooner. "It is akin to whipping a tired horse as it goes uphill," she said.

"It's great to see a new medication being tested and developed," Hamilton said. But, "we are far away from the finish line."

More information

To learn more about heart failure, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Michele Hamilton, M.D., director, heart failure program, Cedars-Sinai Heart Institute, Los Angeles; John R. Teerlink, M.D., cardiologist, San Francisco Veterans Affairs Medical Center, San Francisco; Ronald Zolty, M.D., Ph.D., director, heart failure program, Albert Einstein College of Medicine, Bronx, N.Y.; Aug. 20, 2011, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Putting the squeeze on fat cells
2. ICU Patients at Risk for Rare Heart Rhythm Problem
3. Cook With Love This Valentines Day With Heart-Smart Recipes
4. Study finds racial gaps continue in heart disease awareness
5. Highmark Foundation Awards $120,000 to the American Heart Association
6. Womens Heart Disease Awareness Still Lacking
7. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
8. Migraine Linked to Increased Heart Attack Risk
9. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
10. Compound shows promise against intractable heart failure
11. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Put the Squeeze on Heart Failure
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and ... pancreatic cancer. , Gary D. Radine, who recently retired as president and CEO of ... Society’s 2015 CEO of the Year , helped lead the effort to raise ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research ... U.S. require dental technicians to be certified or obtain continuing education. To increase ... the “What’s In Your Mouth?” campaign to inform dentists and patients about the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
(Date:2/8/2016)... -- --> --> ... Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) ... Gynecology) - Global Forecasts to 2020", published by MarketsandMarkets, ... period of 2015 to 2020. The market is expected ... 10.5% from 2015 to 2020. Browse 73 ...
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
Breaking Medicine Technology: